Monoclonal antibody for recognizing human MSLN protein as well as preparation method and application thereof

By developing monoclonal antibodies against non-extracellular regions I and III of MSLN protein, the problem of insufficient targeting of targeting MSLN protein in the prior art was solved, and a high specific monoclonal antibody was obtained for targeting drugs. and biodetection improves the efficacy.

CN118994399APending Publication Date: 2024-11-22SHANDONG YINFENG LIFE SCIENCE RESEARCH INSTITUTE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411364200.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-28
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Most of the existing antibodies target extracellular regions I and III of MSLN proteins, and lack monoclonal antibodies targeting extracellular non-region I and III of MSLN, which affects the specificity and efficiency of targeted therapies.

Method used

By using Yiqiao Shenzhou commercialized product 13128-H08H1 (296aa~580aa) as an immunogen, immunized mice, combined with ELISA and flow detection, monoclonal antibodies that recognize human MSLN protein were obtained, and targeted the non-extracellular region of MSLN protein were targeted. Ⅰ and region III, hybridoma cells were obtained by electrofusion and purified to obtain stable secreted monoclonal antibodies.

Benefits of technology

Monoclonal antibodies with good specificity were obtained, which can be used for targeted antibody drugs or biological detection, improving the recognition accuracy and efficacy of MSLN protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994399A_ABST
    Figure CN118994399A_ABST
Patent Text Reader

Abstract

The invention discloses a monoclonal antibody for recognizing human MSLN protein as well as a preparation method and application thereof, and belongs to the technical field of monoclonal antibodies. The preparation method of the monoclonal antibody comprises the following steps: (1) taking a Yiqiao Shenzhou commercial product 13128-H08H1 (296aa-580aa) as an immunogen to immunize a mouse; (2) taking blood after immunization, and performing serum titer ELISA detection and flow type detection; (3) performing hybridoma fusion screening and limited dilution to obtain hybridoma cells; (4) the hybridoma cells are cultured and purified, the monoclonal antibody is obtained, the nucleotide sequences of variable regions are shown as SEQ ID NO.1 and SEQ ID NO.2, and the corresponding amino acid sequences are shown as SEQ ID NO.3 and SEQ ID NO.4. The invention also discloses a preparation method of the monoclonal antibody. The monoclonal antibody provided by the invention has good specificity, and can be used for targeted antibody drugs or biological detection experiments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a monoclonal antibody for recognizing human MSLN protein and a preparation method and application thereof, belonging to the technical field of monoclonal antibodies. Background Art

[0002] Mesothelin (MSLN) was initially discovered to be an antigen that can be specifically recognized by the monoclonal antibody K1. CDNA was extracted from the gene library of the HELA cell line that reacts with K1 and the MSLN gene was cloned. Since the membrane-bound protein encoded by this gene is mainly located on the surface of normal mesothelial cells, it was named mesothelin. The mesothelin gene is located on chromosome 16p13. The mesothelin gene MSLN contains 17 exons, the cDNA is about 2138bp long, contains an open reading frame of 1884bp, and encodes a precursor protein of 628 amino acids (69kDa). The precursor protein can be hydrolyzed by Furin protease into two parts: a 40kDa fragment of mesothelin and a 31kDa secretory fragment, called megakaryocyte-potentiating factor (MPF). MSLN is a 40kDa membrane-bound protein, anchored to the cell membrane by glycosylated phosphatidylinositol. Its extracellular domain consists of region I (N-terminal region, residues 296-390), region II (residues 391-486) ​​and region III (C-terminal region, residues 487-598). At present, the biological function of MSLN is not fully understood, but in recent years, it has been found that MSLN, as a tumor differentiation antigen, is overexpressed in malignant tumors such as malignant mesothelioma, lung cancer, esophageal cancer, pancreatic cancer, cervical cancer and ovarian cancer. Among them, MSLN protein is expressed in 85% to 90% of mesothelioma, 80% to 85% of pancreatic cancer and 60% to 65% of lung cancer, ovarian cancer and bile duct cancer, but is almost not expressed in normal tissues (only a small amount is expressed in the peritoneum, pericardium and other locations), making it an excellent target for targeted therapy.

[0003] At present, there are many targeted drugs developed with MSLN as the target, including cancer vaccines, ADC drugs, CAR-T / NK cell therapy, monoclonal antibody drugs, etc. Overall, most of them are antibody-related drugs. Most of the antibodies used in the market target the extracellular region I (N-terminal region, residues 296-390) and region III (C-terminal region, residues 487-598) of MSLN. Summary of the invention

[0004] In view of the above-mentioned prior art, the present invention provides a monoclonal antibody against human MSLN protein, which targets the extracellular region of MSLN (non-extracellular region I and region III), has good specificity, and can be used for targeted antibody drugs or in biological detection experiments.

[0005] The present invention is achieved through the following technical solutions:

[0006] The method for preparing a monoclonal antibody that recognizes human MSLN protein comprises the following steps:

[0007] (1) Immunization: The commercialized product 13128-H08H1 (296aa-580aa) of Sino Biological was used as an immunogen to immunize mice;

[0008] (2) Detection: One week after the third immunization, blood was collected and serum titer ELISA was performed using the coated immunogen 13128-H08H1 (296aa-580aa), and flow cytometry was performed using OVCAR-3 cells;

[0009] (3) Obtaining hybridoma cells: Select one mouse with the best test result for hybridoma fusion screening and limiting dilution, obtain spleen cells from the immunized mouse, mix them with SP2 / 0 myeloma cells at a ratio of 1:1, and fuse them by electrofusion to obtain hybridoma cells;

[0010] (4) Preparation and purification of monoclonal antibodies: Hybridoma cells are cultured and purified to obtain monoclonal antibodies that recognize human MSLN protein.

[0011] Furthermore, the specific operation method of step (1) is as follows: for the first immunization, the immunogen is mixed with an equal volume of complete Freund's adjuvant to prepare an emulsion, which is injected subcutaneously at multiple points in the abdomen; after an interval of 2 weeks, the same dose of the immunogen is mixed with an equal volume of incomplete Freund's adjuvant to prepare an emulsion, which is injected subcutaneously at multiple points in the abdomen; after another interval of 2 weeks, the same dose of the immunogen is mixed with an equal volume of incomplete Freund's adjuvant to prepare an emulsion, which is injected subcutaneously at multiple points in the abdomen; the single immunization dose for each mouse is 50 μg.

[0012] Furthermore, in step (2), the OD450-Blank greater than 0.8 when the mouse serum is diluted 1:8000 is used as the qualified titer standard, and the steps of ELISA detection are as follows:

[0013] (1) Coating: Take an appropriate amount of synthetic protein MSLN (296aa-580aa), antigen region I (296aa-390aa) and antigen region III (487aa-605aa), dissolve and dilute to 5 μg / mL with coating buffer, then add 100 μL to each well of a 96-well plate with a pipette, tap the plate to mix the sample, seal it with plastic wrap, and coat overnight at 4°C;

[0014] (2) Washing: Wash the plate once with washing solution at 300 μL / well and dry the ELISA plate;

[0015] (3) Blocking: Block the ELISA plate with blocking solution at 300 μL / well for 1 h at room temperature;

[0016] (4) Washing: Wash the plate twice with washing solution at 300 μL / well and dry the ELISA plate;

[0017] (5) Sample loading: Add the serially diluted serum sample and sample diluent at 100 μL / well;

[0018] (6) Adding secondary antibody: Add detection antibody at 100 μL / well to a 96-well plate and incubate at room temperature for 2 h;

[0019] (7) Washing: Wash the plate 5 times with washing solution at 300 μL / well and dry the ELISA plate;

[0020] (8) Color development: Add 200 μL / well of color development solution and incubate at room temperature for 12 min;

[0021] (9) Termination and detection: 50 μL / well of stop solution was added to terminate the reaction, and then the reaction was detected using an ELISA reader at a wavelength of 450 nm.

[0022] Furthermore, in step (2), the flow cytometry detection steps are as follows:

[0023] (1) Cell resuspension: Centrifuge the cells and discard the supernatant. Add washing solution and resuspend. Filter through a 400-mesh filter. Centrifuge and wash the cells once. Add an appropriate amount of washing solution and resuspend the cells to adjust the density to 1×10 7 cells / mL, dispensed into flow tubes, 50 μL per tube;

[0024] (2) Primary antibody incubation: Add diluted mouse serum, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0025] (3) Secondary antibody incubation: Add 2 μL of mouse secondary antibody, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0026] (4) Detection: Add 50 μL of washing solution to resuspend the cells and detect them on the same day.

[0027] Furthermore, the specific operation method of step (3) is as follows: spleen cells of immunized mice are obtained, mixed with mouse myeloma cells at a ratio of 1:1, and fused by electrofusion to obtain hybridoma cells; on the 6th day and the 8th day after fusion, the cell medium is replaced once using HAT selection medium; on the 10th day after cell fusion, the supernatant of the cells at the master clone stage is obtained for screening and detection, and the positive master clone cells binding to the antigen protein are screened by the indirect ELISA method; the master clone is subjected to 2 to 3 consecutive rounds of limiting dilution and corresponding screening until a stable monoclonal cell line is obtained.

[0028] Furthermore, in step (4), the specific operation method of culturing hybridoma cells is as follows: 1 mL of hybridoma cells is transferred into a 100 mL culture bottle, and a certain amount of culture medium is added regularly to expand the cells to the required production volume. Then, the hybridoma feed solution is added, and the feed is added every other day. The feed is collected after 6 to 8 days of culture.

[0029] Furthermore, in step (4), the specific operation method of purification is: using protein A affinity purification method to purify the hybridoma cell culture supernatant after centrifugation to harvest monoclonal antibodies. Furthermore, the operation steps are as follows:

[0030] (1) Select a protein A column of appropriate specifications according to the expression level;

[0031] (2) Water balance: Wash with ultrapure water for 2CV and replace the 25% ethanol storage solution;

[0032] (3) Equilibration of chromatography column: AC Binding + 1 / 5 stock buffer for 10 CV;

[0033] (4) Loading: Pour the sample;

[0034] (5) Elution: Elution with eluent for 5-10 CV until the protein column is in equilibrium;

[0035] (6) Elution: AC elution, discard the first 1CV and collect the last 1.5CV;

[0036] (7) Neutralization: Add 2 M Tris, pH 8.0 to neutralize the eluted antibody;

[0037] (8) Balance: AC Binding balance 5CV to neutral;

[0038] (9) CIP cleaning: CIP cleaning for more than 5CV;

[0039] (10) Alkali flushing: AC Binding flushing alkali until the pH at the outlet is neutral;

[0040] (11) Storage: Equilibrate the column with 25% ethanol for 2CV.

[0041] The monoclonal antibody recognizing human MSLN protein prepared by the above method has a nucleotide sequence of the variable region VL as shown in SEQ ID NO.1, a nucleotide sequence of the variable region VH as shown in SEQ ID NO.2, an amino acid sequence of the variable region VL as shown in SEQ ID NO.3, and an amino acid sequence of the variable region VH as shown in SEQ ID NO.4.

[0042] The monoclonal antibody for recognizing human MSLN protein is used for specifically recognizing mesothelin, and is used for preparing a preparation for specifically recognizing mesothelin.

[0043] The preparation method of the monoclonal antibody of the present invention first uses the commercialized product 13128-H08H1 (296aa~580aa) of Yiqiao Shenzhou as an immunogen to immunize 5 mice, and the immunized mice are subjected to serum titer detection. The coated immunogen 13128-H08H1 (296aa~580aa) is used for serum titer ELISA detection, and OVCAR-3 cells are used for flow cytometry detection. After the serum titer ELISA and flow cytometry are qualified, one mouse with the best test results is selected for hybridoma fusion screening and limiting dilution, and the spleen cells of the immunized mice are taken and mixed with SP2 / 0 myeloma cells in a 1:1 ratio, and fused by electric fusion to obtain hybridoma cells. After screening the positive clones, subcloning is performed by 1 to 2 steps of limiting dilution until a hybridoma cell line that stably secretes monoclonal antibodies is obtained, and the antibody variable region sequence is obtained, and the obtained monoclonal antibodies are respectively verified by ELISA and flow cytometry.

[0044] The present invention obtains a hybridoma cell line that stably secretes monoclonal antibodies and obtains antibody variable region sequences. The obtained monoclonal antibodies have good specificity and can be used for targeted antibody drugs or for biological detection experiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 : Flow cytometry detection results of monoclonal antibodies against MSLN.

[0046] Figure 2 : Purity test results of monoclonal antibody against MSLN. DETAILED DESCRIPTION

[0047] The present invention will be further described below in conjunction with the embodiments. However, the scope of the present invention is not limited to the following embodiments. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.

[0048] The instruments, reagents, and materials involved in the following examples, unless otherwise specified, are all conventional instruments, reagents, and materials already available in the prior art and can be obtained through regular commercial channels. The experimental methods and detection methods involved in the following examples, unless otherwise specified, are all conventional experimental methods and detection methods already available in the prior art.

[0049] Example 1 Preparation and detection of monoclonal antibodies

[0050] 1. Hybridoma cell preparation and screening

[0051] 1.1 Immunization of mice

[0052] Five mice were immunized using Yi Biological Shenzhou's commercialized product 13128-H08H1 (296aa~580aa) as an immunogen, with a single immunization dose of 50μg for each mouse. For the first immunization, the immunogen was mixed with an equal volume of complete Freund's adjuvant to make an emulsion, which was injected subcutaneously at multiple points in the abdomen; after an interval of 2 weeks, the same dose of the immunogen was mixed with an equal volume of incomplete Freund's adjuvant to make an emulsion, which was injected subcutaneously at multiple points in the abdomen; after another interval of 2 weeks, the same dose of the immunogen was mixed with an equal volume of incomplete Freund's adjuvant to make an emulsion, which was injected subcutaneously at multiple points in the abdomen. Blood was collected one week after the three immunizations, and the serum titer was determined using indirect ELISA. The OD450-Blank greater than 0.8 when the mouse serum was diluted 1:8000 was considered a qualified titer standard. The animal serum with qualified titer was sent for flow cytometry, and one mouse with the best test result was selected for high-dose shock immunization. The mouse spleen was taken for hybridoma fusion 3 to 4 days after shock immunization.

[0053] 1.2 Serum ELISA and flow cytometry screening

[0054] 1.2.1ELISA

[0055] The detection steps are as follows:

[0056] (1) Coating: Take an appropriate amount of synthetic protein MSLN (296aa-580aa), antigen region I (296aa-390aa) and antigen region III (487aa-605aa), dissolve and dilute to 5 μg / mL with coating buffer, then add 100 μL to each well of a 96-well plate with a pipette, tap the plate to mix the sample, seal it with plastic wrap, and coat overnight at 4°C;

[0057] (2) Washing: Wash the plate once with washing solution at 300 μL / well and dry the ELISA plate;

[0058] (3) Blocking: Block the ELISA plate with blocking solution at 300 μL / well for 1 h at room temperature;

[0059] (4) Washing: Wash the plate twice with washing solution at 300 μL / well and dry the ELISA plate;

[0060] (5) Sample loading: Add the serially diluted serum sample and sample diluent at 100 μL / well;

[0061] (6) Adding secondary antibody: Add detection antibody at 100 μL / well to a 96-well plate and incubate at room temperature for 2 h;

[0062] (7) Washing: Wash the plate 5 times with washing solution at 300 μL / well and dry the ELISA plate;

[0063] (8) Color development: Add 200 μL / well of color development solution and incubate at room temperature for 12 min;

[0064] (9) Termination and detection: 50 μL / well of stop solution was added to terminate the reaction, and then the reaction was detected using an ELISA reader at a wavelength of 450 nm.

[0065] 1.2.2 Flow cytometry

[0066] Flow cytometry was used to perform intervention detection on the mouse serum with qualified titer. The detection steps are as follows:

[0067] (1) Cell resuspension: Centrifuge the cells and discard the supernatant. Add washing solution and resuspend. Filter through a 400-mesh filter. Centrifuge and wash the cells once. Add an appropriate amount of washing solution and resuspend the cells to adjust the density to 1×10 7 cells / mL, dispensed into flow tubes, 50 μL per tube;

[0068] (2) Primary antibody incubation: Add diluted mouse serum, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0069] (3) Secondary antibody incubation: Add 2 μL of mouse secondary antibody, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0070] (4) Detection: Add 50 μL of washing solution to resuspend the cells and detect them on the same day.

[0071] 1.3 Hybridoma cell screening

[0072] 1.3.1 Hybridoma cell preparation

[0073] Take the spleen cells of immunized mice, mix them with mouse myeloma cells at a ratio of 1:1, and fuse them by electrofusion to obtain hybridoma cells. On the 6th and 8th day after fusion, use HAT selection medium to change the cell medium once; on the 10th day after cell fusion, take the supernatant of the master clone stage cells for screening and detection, and use the indirect ELISA method to screen and obtain positive master clone cells that bind to the antigen protein. The master clone undergoes 2 to 3 consecutive rounds of limiting dilution and corresponding screening until a stable monoclonal cell line is obtained.

[0074] 1.3.2 ELISA binding screening

[0075] The indirect ELISA method is used to perform binding detection on the hybridoma cell culture supernatant, and the clones that bind to the antigen are retained. The detection process is as follows:

[0076] (1) Coating: Take appropriate amounts of synthetic protein MSLN (296aa-580aa), antigen region I (296aa-390aa), and antigen region III (487aa-605aa), dissolve them in coating buffer and dilute them to 0.1 μg / mL and 1 μg / mL, respectively. Then, add 100 μL to each well of a 96-well plate using a pipette, tap the plate to mix the sample, seal it with plastic wrap, and coat overnight at 4°C.

[0077] (2) Blocking: Shake off the solution and block the ELISA plate with blocking solution at 300 μL / well for 1 h at room temperature;

[0078] (3) Sample loading: Shake off the liquid and dry the ELISA plate; add 50 μL / well of hybridoma cell supernatant and leave at room temperature for 1 h;

[0079] (4) Washing: Wash the plate once with washing solution at 300 μL / well and dry the ELISA plate;

[0080] (5) Adding secondary antibody: Add detection antibody at 100 μL / well to a 96-well plate and incubate at room temperature for 2 h;

[0081] (6) Washing: Wash the plate 5 times with washing solution at 300 μL / well and dry the plate;

[0082] (7) Color development: Add 200 μL / well of color development solution and leave at room temperature for 16 min for the first screening and 8 min for the second screening and subcloning;

[0083] (8) Termination and detection: 50 μL / well of stop solution was added to terminate the reaction, and then the reaction was detected using an ELISA reader at a wavelength of 450 nm.

[0084] 1.3.3 Flow cytometry intervention screening

[0085] The flow cytometry method was used to perform intervention screening on the supernatant of ELISA-positive hybridoma cells. The detection steps were as follows:

[0086] (1) Cell resuspension: Centrifuge the cells and discard the supernatant. Add washing solution and resuspend. Filter through a 400-mesh filter. Centrifuge and wash the cells once. Add an appropriate amount of washing solution and resuspend the cells to adjust the density to 1×10 7 cells / mL, dispensed into flow tubes, 50 μL per tube;

[0087] (2) Primary antibody incubation: Add the supernatant of the hybridoma cells to be tested, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0088] (3) Secondary antibody incubation: Add 2 μL of mouse secondary antibody, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once;

[0089] (4) Detection: Add 50 μL of washing solution to resuspend the cells and detect them on the same day.

[0090] 1.4 Hybridoma cell gene extraction and construction

[0091] (1) Extract RNA after hybridoma cell lysis;

[0092] (2) Reverse transcription: Using the extracted RNA as a template, a reverse transcription kit is used to obtain cDNA in two steps (first opening the RNA secondary structure, then allowing the primer to bind to the RNA and polymerize the cDNA to achieve the purpose of obtaining cDNA);

[0093] (3) Using the cDNA obtained by reverse transcription as a template, amplify the fragment by PCR, insert it into the vector, and sequence it to obtain a plasmid containing the correct sequence.

[0094] 2. Purified Antibody Testing

[0095] 2.1 Hybridoma cell culture

[0096] Transfer 1 mL of hybridoma cells into a 100 mL culture flask, add a certain amount of culture medium regularly to expand the cells until the cells reach the required production volume. Then add hybridoma feed solution, feed every other day. Collect the feed after 6 to 8 days of culture.

[0097] 2.2 Hybridoma Antibody Purification

[0098] The hybridoma cell culture supernatant after centrifugation was purified using protein A affinity purification method to harvest mouse monoclonal antibodies. The operation steps are as follows:

[0099] (1) Select a protein A column of appropriate specifications according to the expression level;

[0100] (2) Water balance: Wash with ultrapure water for 2CV and replace the 25% ethanol storage solution;

[0101] (3) Equilibration of chromatography column: AC Binding + 1 / 5 stock buffer for 10 CV;

[0102] (4) Loading: Pour the sample;

[0103] (5) Elution: Elution with eluent for 5-10 CV until the protein column is in equilibrium;

[0104] (6) Elution: AC elution, discard the first 1CV and collect the last 1.5CV;

[0105] (7) Neutralization: Add 2 M Tris, pH 8.0 to neutralize the eluted antibody;

[0106] (8) Balance: AC Binding balance 5CV to neutral;

[0107] (9) CIP cleaning: CIP cleaning for more than 5CV;

[0108] (10) Alkali flushing: AC Binding flushing alkali until the pH at the outlet is neutral;

[0109] (11) Storage: Equilibrate the column with 25% ethanol for 2CV.

[0110] 2.3 Antibody purity detection

[0111] The purity of the purified antibody was verified by polyacrylamide gel electrophoresis (SDS-PAGE). This method verifies the purity of the target antibody by separating the proteins in the test sample in the electrophoresis gel according to their different molecular weights. Take 5μg of the test sample, add 5μL 4R / 4N, heat in a 100℃ water bath, and then centrifuge at 10000rpm. Add sufficient 1×SDS electrode buffer to the electrophoresis tank, and use a micropipette to add the treated sample solution and protein molecular weight standard to the sample well. Connect the power supply, first electrophoresed at a constant voltage of 100V until the bromophenol blue dye enters the separation gel from the stacking gel, then adjust the current to 140V and continue electrophoresis to the bottom of the gel plate, and turn off the power. Soak the gel in the staining solution, heat it in a microwave oven for 60s, and stain it at room temperature on a gently shaking platform. Replace the destaining solution to cover the gel, heat it in a microwave oven for 60s, destain it at room temperature on a gently shaking platform, and repeat the destaining operation until a blue band and a clean background are obtained.

[0112] 2.4 ELISA binding assay

[0113] The indirect ELISA method was used to detect the binding of purified mouse monoclonal antibodies to the immunogen. The detection process is as follows:

[0114] (1) Coating: Take appropriate amount of synthetic protein MSLN (296aa-580aa), antigen region I (296aa-390aa), and antigen region III (487aa-605aa), dissolve and dilute to 0.1 μg / mL and 1 μg / mL respectively with coating buffer, 100 μL / well, and coat overnight at 4°C;

[0115] (2) Blocking: shake off the liquid in the plate and pat dry, add 2% BSA, 300 μL / well, seal and incubate at room temperature for 1 h;

[0116] (3) Washing: 300 μL / well washing solution, wash the plate twice, and pat dry for the last time;

[0117] (4) Antibody dilution and sample addition: dilute the QLY4-1 antibody to 1 μg / mL, add 100 μL of each to the corresponding well plate, mix well, and react at room temperature for 2 h;

[0118] (5) Washing: 300 μL / well washing solution, wash the plate 3 times, and pat dry for the last time;

[0119] (6) Secondary antibody incubation: dilute Rabbit Anti-Mouse IgG F(ab')2 / HRP secondary antibody to the working concentration, 100 μL / well, mix well, and incubate at room temperature for 1 h;

[0120] (7) Washing: 300 μL / well washing solution, wash the plate 3 times, and pat dry for the last time;

[0121] (8) Color development: Mix solution A and solution B at a ratio of 1:1, add 200 μL to each well, and incubate at room temperature in the dark for 20 min;

[0122] (9) Termination and detection: Add 50 μL of stop solution to each well and immediately measure the OD value at a wavelength of 450 nm.

[0123] 2.4 Flow cytometry

[0124] Same as 1.3.3.

[0125] 3. Results

[0126] 3.1 ELISA test results

[0127] The results of ELISA test of monoclonal antibody against MSLN are shown in Table 1.

[0128] Table 1

[0129]

[0130]

[0131] 3.2 Flow cytometry results

[0132] The flow cytometry results of the monoclonal antibody against MSLN are shown in Figure 1 shown.

[0133] 3.3 Variable region nucleotide sequence and amino acid sequence

[0134] The nucleotide sequences of the variable regions of the monoclonal antibodies against MSLN are shown in SEQ ID NO.1 and SEQ ID NO.2, and the corresponding amino acid sequences are shown in SEQ ID NO.3 and SEQ ID NO.4.

[0135] The nucleotide sequence of VL is as follows (direction 5'-3'), as shown in SEQ ID NO.1:

[0136] GACATCAAGATGACCCAGTCTCCATCCTCCATGTATGCATCGCTGGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGACATTGAAACCTATTTAAGCTGGTACCAGCAGAAACCATGGAAATCTCCTAAGACCCTGATCTATTCTGCAACAAGCCTGGCAGATGGGGTCCCATCAAGATTCAGTGGCAGTGGATCTGGACAAGAGTTTTCTCTAACCATCAACAGCCTGGAGTCTGACGATACAGCAACTTATTACTGTCTACAGATTACTGAGAGCCCGCACACGTTCGGTGGTGGGACCAAGTTGGAGCTGAAA。

[0137] The nucleotide sequence of VH is shown below (in the 5'-3' direction) and is as shown in SEQ ID NO.2:

[0138] GAGGTCCACCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTAGCTATGTTATGCACTGGGTAAAGCAGAAGTCTGGACAGGGCCTTGAGTGGATCGGATATTTTAATCCCTACAATGATGTTACTAAGTACACTGAGAAGTTCAAAGGCAAGGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGACCTCAGCAGCCTGACTTCTGAGGACTCTGCGGTCTATTACTGTGCAAGAGAGGGACGGGGTTATTACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA。

[0139] The amino acid sequence of VL is shown below and is as shown in SEQ ID NO.3:

[0140] DIKMTQSPSSMYASLGERVTITCKASQDIETYLSWYQQKPWKSPKTLIYSATSLADGVPSRFSGSGSGQEFSLTIN SLESDDTATYYCLQITESPHTFGGGTKLELK。

[0141] The amino acid sequence of VH is shown below, as shown in SEQ ID NO.4:

[0142] EVHLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKSGQGLEWIGYFNPYNDVTKYTEKFKGKATLTSDKSS STAYMDLSSLTSEDSAVYYCAREGRGYYYAMDYWGQGTSVTVSS.

[0143] 3.4 Purity test results

[0144] The purity test results of the monoclonal antibody against MSLN are as follows Figure 2 shown.

[0145] From the above test results, it can be seen that the present invention has obtained a hybridoma cell line that stably secretes monoclonal antibodies and obtained the antibody variable region sequence. The obtained monoclonal antibodies have good specificity and can be used for targeted antibody drugs or in biological detection experiments.

[0146] The above examples are provided to those skilled in the art to fully disclose and describe how to make and use the claimed embodiments, and are not intended to limit the scope of the disclosure herein. Modifications that are obvious to those skilled in the art will fall within the scope of the appended claims.

Claims

1. Preparation of monoclonal antibodies that recognize human MSLN protein, It is characterized in that The following steps are involved: (1) Immunization: The commercialized product 13128-H08H1 (296aa-580aa) of Sino Biological was used as the immunogen to immunize mice; (2) Detection: One week after the third immunization, blood was collected and serum titer ELISA was performed using the coated immunogen 13128-H08H1 (296aa-580aa), and flow cytometry was performed using OVCAR-3 cells; (3) Obtaining hybridoma cells: Select one mouse with the best test result for hybridoma fusion screening and limiting dilution, obtain spleen cells from the immunized mouse, mix them with SP2 / 0 myeloma cells at a ratio of 1:1, and fuse them by electrofusion to obtain hybridoma cells; (4) Preparation and purification of monoclonal antibodies: Hybridoma cells are cultured and purified to obtain monoclonal antibodies that recognize human MSLN protein.

2. The preparation method according to claim 1, It is characterized in that The specific operation method of step (1) is as follows: for the first immunization, the immunogen and an equal volume of complete Freund's adjuvant are prepared into an emulsion, and the emulsion is injected subcutaneously at multiple points in the abdomen; after an interval of 2 weeks, the same dose of the immunogen and an equal volume of incomplete Freund's adjuvant are prepared into an emulsion, and the emulsion is injected subcutaneously at multiple points in the abdomen; after another interval of 2 weeks, the same dose of the immunogen and an equal volume of incomplete Freund's adjuvant are prepared into an emulsion, and the emulsion is injected subcutaneously at multiple points in the abdomen; the single immunization dose for each mouse is 50 μg.

3. The preparation method according to claim 1, It is characterized in that In the step (2), the OD450-Blank greater than 0.8 when the mouse serum is diluted 1:8000 is used as the qualified titer standard, and the steps of ELISA detection are as follows: (1) Coating: Take an appropriate amount of synthetic protein MSLN (296aa-580aa), antigen region I (296aa-390aa) and antigen region III (487aa-605aa), dissolve and dilute to 5 μg / mL with coating buffer, then add 100 μL to each well of a 96-well plate with a pipette, tap the plate to mix the sample, seal it with plastic wrap, and coat overnight at 4°C; (2) Washing: Wash the plate once with washing solution at 300 μL / well and dry the ELISA plate; (3) Blocking: Block the ELISA plate with blocking solution at 300 μL / well for 1 h at room temperature; (4) Washing: Wash the plate twice with washing solution at 300 μL / well and dry the ELISA plate; (5) Sample loading: Add the serially diluted serum sample and sample diluent at 100 μL / well; (6) Adding secondary antibody: Add detection antibody at 100 μL / well to a 96-well plate and incubate at room temperature for 2 h; (7) Washing: Wash the plate 5 times with washing solution at 300 μL / well and dry the plate; (8) Color development: Add 200 μL / well of color development solution and incubate at room temperature for 12 min; (9) Termination and detection: 50 μL / well of stop solution was added to terminate the reaction, and then the reaction was detected using an ELISA reader at a wavelength of 450 nm.

4. The preparation method according to claim 1, It is characterized in that In step (2), the flow detection steps are as follows: (1) Cell resuspension: Centrifuge the cells and discard the supernatant. Add washing solution and resuspend. Filter through a 400-mesh filter. Centrifuge and wash the cells once. Add an appropriate amount of washing solution and resuspend the cells to adjust the density to 1×10 7 cells / mL, dispensed into flow tubes, 50 μL per tube; (2) Primary antibody incubation: Add diluted mouse serum, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once; (3) Secondary antibody incubation: Add 2 μL of mouse secondary antibody, mix well, incubate at 4°C in the dark for 20 min, add washing solution and centrifuge to wash the cells once; (4) Detection: Add 50 μL of washing solution to resuspend the cells and detect them on the same day.

5. The preparation method according to claim 1, It is characterized in that The specific operation method of step (3) is as follows: spleen cells of immunized mice are obtained, mixed with mouse myeloma cells at a ratio of 1:1, and fused by electrofusion to obtain hybridoma cells; on the 6th day and the 8th day after fusion, the cell medium is replaced once using HAT selection medium; on the 10th day after cell fusion, the supernatant of the cells at the master clone stage is obtained for screening and detection, and the positive master clone cells binding to the antigen protein are screened by the indirect ELISA method; the master clone is subjected to 2 to 3 consecutive rounds of limiting dilution and corresponding screening until a stable monoclonal cell line is obtained.

6. The preparation method according to claim 1, It is characterized in that In the step (4), the specific operation method of culturing hybridoma cells is as follows: 1 mL of hybridoma cells is transferred into a 100 mL culture bottle, a certain amount of culture medium is added regularly to expand the cells to the required production volume; then, hybridoma feed solution is added, and feed is added every other day; and the feed is collected after culturing for 6 to 8 days.

7. The preparation method according to claim 1, It is characterized in that In the step (4), the specific operation method of purification is: using protein A affinity purification method to purify the hybridoma cell culture supernatant after centrifugation to harvest monoclonal antibodies.

8. A monoclonal antibody that recognizes human MSLN protein and is produced by the production method according to any one of claims 1 to 7.

9. The monoclonal antibody recognizing human MSLN protein according to claim 8, Features: The nucleotide sequence of the variable region VL is shown in SEQ ID NO.1, the nucleotide sequence of the variable region VH is shown in SEQ ID NO.2, the amino acid sequence of the variable region VL is shown in SEQ ID NO.3, and the amino acid sequence of the variable region VH is shown in SEQ ID NO.

4.

10. Use of the monoclonal antibody recognizing human MSLN protein according to claim 8 or 9 in specifically recognizing mesothelin, or in preparing a preparation specifically recognizing mesothelin.